China Meheco Subsidiary Tianfang Pharmaceutical Approved as Marketing Authorization Holder for Bumetanide Injection

Regulation
โดย Jiemian·Read original
Summary · why it matters

China Meheco announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received the Drug Supplementary Application Approval Notice for Bumetanide Injection issued by the National Medical Products Administration. The marketing authorization holder for this drug has been changed from Shenzhen Glein Biomedical Technology to Tianfang Pharmaceutical, with the drug approval number remaining unchanged. The production site, formulation, manufacturing process, and quality standards remain consistent with the original drug. Bumetanide Injection is used to treat edema associated with congestive heart failure, hypertension, liver disease, and kidney disease.

Impact on stocks 1

Others▲ · 1 stocks
China Meheco Co Ltd
600056
▲ PositiveRegulationrelevance

Tianfang Pharmaceutical, a wholly-owned subsidiary, was approved as the marketing authorization holder for Bumetanide Injection, expanding its product portfolio.

Off-coverage companies 1

深圳格莱恩生物医药科技有限公司Private▼ Negative
Regulationrelevance

Shenzhen Glein Biomedical Technology lost the marketing authorization holder status for Bumetanide Injection to Tianfang Pharmaceutical.

© 2026 MarketDXNews